- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bio-Thera Solutions' Biosimilar Adalimumab Launches in China
It is the first adalimumab biosimilar approved by the China National Medical Products Administration.
Bio-Thera Solutions said Friday that Qleti, a biosimilar adalimumab referencing Humira, is now available in China.
It is the first adalimumab biosimilar approved by the China National Medical Products Administration (NMPA) and is authorized for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.
Bio-Thera's said it is the first of its biosimilars to receive regulatory approval and is the second biosimilar approved in China by the NMPA.
Bio-Thera announced in July 2019 that the biosimilar, BAT1406, had met its primary end point of equivalent efficacy to reference adalimumab in a phase 3 trial conducted in patients with active ankylosing spondylitis.
The application submitted to the regulatory authorities included a comprehensive data package that consists of analytical, preclinical, and clinical data. The clinical studies included a trial that investigated pharmacokinetic and pharmacodynamic data, as well as the phase 3 study in AS.
The drug maker is also developing biosimilar candidates of bevacizumab, tocilizumab, ustekinumab, and golimumab.
“The commercial launch of Bio-Thera’s first approved product is an enormous milestone for the company," said Shengfeng Li, PhD, chief executive officer of Bio-Thera Solutions, in a statement. "It demonstrates that Bio-Thera Solutions is a fully-integrated pharmaceutical company, able to take a product developed in our labs, through the clinic, through regulatory approval and now to the market. Bio-Thera is committed to bringing additional biosimilar and innovative products to the market in China and around the world."
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
